GlassScriptPhysician profile
Kim M Heim
NPI 1548602154
$1,208.94
in general payments reported to CMS, 2019-2025
14 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $81.27 · 2023: $392 · 2024: $145 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744 · Education: $284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.70 |
| Education | $283.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $250.01 | 2022-2025 | |
| Astellas Pharma US INC | $185.98 | 2025 | |
| Janssen Biotech, INC. | $164.32 | 2023-2025 | Darzalex, Talvey |
| Abbvie INC. | $142.85 | 2021-2025 | |
| Lilly USA, LLC | $124.85 | 2023 | |
| Glaxosmithkline, LLC. | $71.75 | 2024 | Jemperli, Zejula |
| Caris Mpi, INC. | $53.27 | 2025 | Mi Cancer Seek |
| Genmab U.S., INC. | $44.36 | 2024-2025 | Tivdak |
| Legend Biotech USA INC. | $36.46 | 2025 | Carvykti |
| Merck Sharp & Dohme LLC | $32.35 | 2025 | Keytruda |
| Novartis Pharmaceuticals Corporation | $31.01 | 2025 | |
| Baxter Healthcare | $27.20 | 2024 | Perclot |
| Foundation Medicine, INC. | $24.08 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $20.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kim Heim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.